AMLX (Amylyx Pharmaceuticals) Interest Coverage: N/A (As of Mar. 2026)


AMLX Amylyx Pharmaceuticals Inc AMLX
33 GF Score
Price $17.92
! 2 Warning Signs
View Full Analysis

What is Amylyx Pharmaceuticals Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Amylyx Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was $-43.78 Mil. Amylyx Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Amylyx Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Amylyx Pharmaceuticals's Interest Coverage or its related term are showing as below:


AMLX's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.78
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Amylyx Pharmaceuticals  (NAS:AMLX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Amylyx Pharmaceuticals Interest Coverage Related Terms


Amylyx Pharmaceuticals Interest Coverage Historical Data

* Premium members only.

The historical data trend for Amylyx Pharmaceuticals's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Amylyx Pharmaceuticals Interest Coverage Chart

Amylyx Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Coverage
Get a 7-Day Free Trial No Debt N/A N/A N/A N/A

Amylyx Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

AMLX vs PRGO, ANIP, HROW: Interest Coverage Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Amylyx Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amylyx Pharmaceuticals Interest Coverage vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amylyx Pharmaceuticals's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Amylyx Pharmaceuticals's Interest Coverage falls into.


AMLX
33GF Score
Amylyx Pharmaceuticals Inc AMLX
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amylyx Pharmaceuticals Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Amylyx Pharmaceuticals's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, Amylyx Pharmaceuticals's Interest Expense was $0.00 Mil. Its Operating Income was $-153.29 Mil. And its Long-Term Debt & Capital Lease Obligation was $4.70 Mil.

GuruFocus does not calculate Amylyx Pharmaceuticals's interest coverage with the available data.

Amylyx Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Here, for the three months ended in Mar. 2026, Amylyx Pharmaceuticals's Interest Expense was $0.00 Mil. Its Operating Income was $-43.78 Mil. And its Long-Term Debt & Capital Lease Obligation was $4.48 Mil.

GuruFocus does not calculate Amylyx Pharmaceuticals's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Amylyx Pharmaceuticals Business Description

Address 55 Cambridge Parkway, Suite 6W, Cambridge, MA, USA, 02142
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
33GF Score

Get the complete analysis for AMLX

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.92
Price